NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xinnate AB

Xinnate AB

Private
LundHealthcare & Life Scienceshttps://xinnate.com/

Last Round

VC Round

Dec 18, 2025

Total Funding Raised

$1.77M

Company Overview

Xinnate AB is a pharmaceutical company that develops novel peptide-based therapies for the treatment of inflammatory skin conditions and wounds.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalpeptide therapywound healingepidermolysis bullosaEBimmunomodulatory treatmentorphan drugtopical drugclinical-stage biotechrare disease drugdrug out-licensinginflammatory skin diseasebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xinnate AB Comparables

Compare Xinnate AB with similar companies based on industry and business-model similarity.

Xinnate AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioMendics
80%
Aegle Therapeutics Corp
79%
TWi Biotechnology, Inc.
78%

Xinnate AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 18, 2025
VC RoundJul 1, 2025
GrantJul 1, 2022

Key People

Founding team and executive leadership

Helene Hartman

CEO Xinnate AB

Executive Team

Xinnate AB Investors

Notable investors and investment history

Xinnate AB investors
InvestorRounds
United States Department of DefenseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2022

    $1.77M grant from the United States Department of Defense.

Xinnate AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xinnate AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xinnate AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersLund
Employee Range6
Year Founded2019
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.